AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38410920
Drug: Capecitabine with
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine with immunotherapy (durvalumab and tremelimumab)
Trial: 38410952
Drug: Acute myocardial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute myocardial injury defined as at least 1 high-sensitivity cardiac troponin T value above the upper reference limit (14 ng/L) with a rise/fall of >20%.
Trial: 38410945
Drug: Invasive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive management with angiography, revascularization, and guideline-directed medical therapy
Trial: 38410945
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative management with guideline-directed medical therapy alone
Trial: 38411017
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement containing zinc, vitamins B, calcium, iodine, iron, β-carotene, and folic acid during preconception and pregnancy
Trial: 38411949
Drug: Mindfulness-Based Compassionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Compassionate Living (MBCL) training, twice a week for 4 weeks
Trial: 38411973
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir 1 gm daily for 1 year
Trial: 38413147
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose VKA targeting an international normalised ratio of 2.0-3.0
Trial: 38413147
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral anticoagulation
Trial: 38413246
Drug: Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination therapy
Trial: 38413410
Drug: Asunercept (APG101)
RxNorm normalized name: Asunercept
DrugBank: Asunercept (DB15160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asunercept (APG101) treatment
Trial: 38413540
Drug: Intranasal DHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal DHE powder (STS101) 5.2 mg
Trial: 38413540
Drug: Intranasal DHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal DHE powder (STS101) 7.0 mg
Trial: 38413540
Drug: Intranasal DHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal DHE powder (STS101) 8.6 mg
Trial: 38413540
Drug: Intramuscular DHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular DHE mesylate 1.0 mg
Trial: 38413540
Drug: Liquid nasal
RxNorm normalized name: Zicam Intense Sinus Relief Liquid Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid nasal spray DHE 2.0 mg
Trial: 38413849
Drug: Chronic beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic beta-blocker therapy
Trial: 38413849
Drug: Non-beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-beta-blocker therapy
Trial: 38414003
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CrM) supplementation at 20 g/day
Trial: 38414510
Drug: Tislelizumab immunotherapy
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab immunotherapy
Trial: 38414658
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) administration prior to photodynamic therapy (PDT)
Trial: 38415895
Drug: Sirolimus drug
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus drug coated balloon (DCB)
Trial: 38416223
Drug: THC (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (8 mg THC for a 75-kg person)
Trial: 38416223
Drug: THC +
RxNorm normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC + CBD (8 mg THC and 24 mg CBD for a 75-kg person)
Trial: 38416809
Drug: Systemic metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic metformin (1000 mg/d) with TCA peeling
Trial: 38416809
Drug: Systemic metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic metformin (500 mg/d) with TCA peeling
Trial: 38416865
Drug: Paliperidone Palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone Palmitate Monthly
Trial: 38417017
Drug: Automated Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated Insulin Delivery System with Automatic Meal Bolus
Trial: 38417277
Drug: Glesatinib (MGCD265)
RxNorm normalized name: Glesatinib
DrugBank: Glesatinib (DB06302)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glesatinib (MGCD265) 1050 mg BID (FBS capsule) or 750 mg BID (SDD tablet)
Trial: 38417440
Drug: Single-dose camrelizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose camrelizumab alone (n = 20)
Trial: 38417552
Drug: 30-mL silicone
RxNorm normalized name: CATH,SILICONE 18F 30ML RUSCH #173830180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mL silicone single-balloon catheter
Trial: 38417976
Drug: Dolutegravir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir plus rilpivirine (50 mg dolutegravir plus 25 mg rilpivirine once daily)
Trial: 38417976
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (current antiretroviral therapy regimen)
Trial: 38418234
Drug: Camrelizumab in
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab in combination with chemotherapy (CT)
Trial: 38418306
Drug: Advanced ICCU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced ICCU therapies
Trial: 38418879
Drug: Tiragolumab (anti-TIGIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab (anti-TIGIT antibody) combined with atezolizumab (anti-PD-L1)
Trial: 38419024
Drug: 12-week exercise
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week exercise therapy and education (ExE) and 10-module internet-delivered cognitive behavioral therapy (iCBT)
Trial: 38419030
Drug: Stereotactically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactically guided intracerebral injection of CTX0E03, a fetal derived neural stem cell line.
Trial: 38419032
Drug: Compressive Cryotherapy
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compressive Cryotherapy (CC)
Trial: 38419035
Drug: eclitasertib 600
RxNorm normalized name: ECLITASERTIB
DrugBank: SAR443122 (DB16492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eclitasertib 600 mg (300 mg twice daily)
Trial: 38419787
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg and 25 mg pooled doses)
Trial: 38419981
Drug: Extra-oral suction
RxNorm normalized name: Panadol Extra Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-oral suction (EOS) & low suction
Trial: 38419981
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of suction devices (extra-oral with intra-oral suction, or extra-oral suction with low suction, or high & low suction)
Trial: 38420356
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) injection with evidence-based treatment rationale
Trial: 38420356
Drug: Fixed-time 'Booster'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-time 'Booster' group with one single repetition of the OLP injection at a fixed time point
Trial: 38420356
Drug: On-demand 'Booster'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand 'Booster' group with one single repetition of the OLP injection on-demand
Trial: 38420356
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving just one OLP injection
Trial: 38420657
Drug: elranatamab (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elranatamab (12 mg on day 1, 32 mg on day 4, 76 mg on day 8, each cycle = 28 days)
Trial: 38420809
Drug: Collagen-related cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-related cell adhesion molecules (CAMs) identified through multi-omics data analysis and bioinformatics.
Trial: 38421404
Drug: Venetoclax in
RxNorm normalized name: Product containing venetoclax in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax in combination with rituximab
Trial: 38421404
Drug: Venetoclax in
RxNorm normalized name: Product containing venetoclax in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax in combination with obinutuzumab
Trial: 38421404
Drug: Specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific treatment for TLS
Trial: 38421421
Drug: LNG-IUS-19.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG-IUS-19.5 mg
Trial: 38421757
Drug: Internet-based acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based acceptance and commitment therapy (iACT)
Trial: 38421881
Drug: High ctDNA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High ctDNA levels evaluated by variant allele frequency (VAF) and haploid genome equivalents per milliliter of plasma (hGE/mL) at baseline
Trial: 38421921
Drug: Valbenazine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine (both doses)
Trial: 38422496
Drug: Antibiotics (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (25 mg/kg cefazolin IV up to 1g or clindamycin 10 mg/kg up to 600 mg IV in case of cefazolin allergy)
Trial: 38422496
Drug: Placebo (10-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10-mL prefilled syringe of normal saline)
Trial: 38422585
Drug: CBP501 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBP501 16 mg/m, cisplatin, nivolumab
Trial: 38422585
Drug: CBP501 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBP501 25 mg/m, cisplatin, nivolumab
Trial: 38422585
Drug: CBP501 (unknown
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBP501 (unknown dosage), cisplatin, nivolumab
Trial: 38423021
Drug: BCG-Denmark vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-Denmark vaccination (0.1 mL intradermal injection)
Trial: 38423021
Drug: Placebo (intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intradermal injection of 0.9% saline)
Trial: 38423051
Drug: Pivekimab sunirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivekimab sunirine at 0.045 mg/kg once every 3 weeks (recommended phase 2 dose)
Trial: 38423051
Drug: Pivekimab sunirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivekimab sunirine at doses of 0.015 mg/kg to 0.450 mg/kg (schedule A)
Trial: 38423215
Drug: Low-dose cotoretigene
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cotoretigene toliparvovec (5 × 10^11 vg/mL)
Trial: 38423215
Drug: High-dose cotoretigene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cotoretigene toliparvovec (5 × 10^12 vg/mL)
Trial: 38423215
Drug: Low-dose cotoretigene
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cotoretigene toliparvovec
Trial: 38423215
Drug: High-dose cotoretigene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cotoretigene toliparvovec
Trial: 38423758
Drug: Intervention: TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: TNF inhibitors (TNFi) as a time-varying covariate
Trial: 38423765
Drug: Intravenous thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thiamine (200 mg in 50 mL 0.9% saline)
Trial: 38423770
Drug: Intensive glycaemic
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive glycaemic targets (fasting <90 mg/dL and 1-hour postprandial <120 mg/dL)
Trial: 38423770
Drug: Standard glycaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glycaemic targets (fasting <95 mg/dL and 1-hour postprandial <140 mg/dL)
Trial: 38423866
Drug: Niraparib 1
RxNorm normalized name: niraparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 1 × 300-mg tablet
Trial: 38423866
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 100-mg capsules
Trial: 38423866
Drug: Niraparib 1
RxNorm normalized name: niraparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 1 × 300-mg tablet in fed state (high-fat meal)
Trial: 38423866
Drug: Niraparib 1
RxNorm normalized name: niraparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 1 × 300-mg tablet in fasted state
Trial: 38423992
Drug: Avacopan 30
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avacopan 30 or 60 mg twice daily
Trial: 38423992
Drug: Avacopan co-administered
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avacopan co-administered with itraconazole
Trial: 38423992
Drug: Avacopan co-administered
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avacopan co-administered with rifampin
Trial: 38424308
Drug: Encorafenib (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib (450 mg QD) and binimetinib (45 mg BID)
Trial: 38424308
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg) and Bupropion (75 mg)
Trial: 38424308
Drug: Encorafenib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib (300 mg QD) and cetuximab (400 mg/m2)
Trial: 38424537
Drug: Vortioxetine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (5-20 mg, n=73)
Trial: 38424609
Drug: Integrated exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated exercise intervention (16-week group-based, workouts twice a week, endurance and resistance training)
Trial: 38425141
Drug: Oral megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral megestrol acetate (MA) 160 mg
Trial: 38425284
Drug: Adjunctive brexpiprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive brexpiprazole 0.5-2 mg/day
Trial: 38425504
Drug: Carboplatin (AUC5)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (AUC5) administered intravenously every 21 days for 6-9 cycles
Trial: 38425987
Drug: Irinotecan (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (180 mg/m2) administered in 28-day cycles
Trial: 38426909
Drug: Fully Closed-Loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully Closed-Loop Insulin Delivery
Trial: 38427076
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion during a hyperinsulinaemic-euglycaemic clamp in participants with type 1 diabetes
Trial: 38427076
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion during a hyperinsulinaemic-euglycaemic clamp in healthy participants
Trial: 38427322
Drug: Combination A
RxNorm normalized name: SUNFLOWER OIL 7.92 g in 14 g TOPICAL STICK [OrgaPlus Super Care Balm for combination and oi ly skin type 14g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination A (flexible single-channel EEG headband + actigraphy)
Trial: 38427322
Drug: Combination B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination B (rigid single-channel EEG headband + actigraphy)
Trial: 38428259
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg oral dose
Trial: 38428265
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (Pemetrexed Cisplatin)
Trial: 38428265
Drug: Personalized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized treatment based on EGFR mutation (Erlotinib) and ERCC1 expression
Trial: 38428428
Drug: Idebenone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone treatment (900 mg/day) for 24 months
Trial: 38428681
Drug: Salvage stereotactic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage stereotactic body radiation therapy (SBRT) at 42.5 Gy in 5 fractions
Trial: 38428681
Drug: Salvage stereotactic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage stereotactic body radiation therapy (SBRT) at 40 Gy (DL1)
Trial: 38428681
Drug: Salvage stereotactic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage stereotactic body radiation therapy (SBRT) at 42.5 Gy (DL2)
Trial: 38428681
Drug: Salvage stereotactic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage stereotactic body radiation therapy (SBRT)
Trial: 38429253
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg twice daily)
Trial: 38430272
Drug: Mogamulizumab (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab (0.3 mg/kg intravenous every 12 weeks)
Trial: 38430375
Drug: Durvalumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab monotherapy and durvalumab plus tremelimumab
Trial: 38431131
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of hydrocortisone parenterally every 8 hours for 3 days
Trial: 38431131
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of hydrocortisone
Trial: 38431133
Drug: Tailored medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored medication adherence-promotion intervention
Trial: 38431156
Drug: AZD1222 (ChAdOx1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1222 (ChAdOx1 nCov-19) two-dose primary series
Trial: 38431445
Drug: Hemin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemin (4 mg/kg)
Trial: 38431766
Drug: Systemic or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic or topical interventions (specifics not provided)
Trial: 38432233
Drug: Tebipenem pivoxil
RxNorm normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebipenem pivoxil hydrobromide (600 mg orally every 8 h)
Trial: 38432233
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid (500 mg amoxicillin and 125 mg clavulanic acid orally every 8 h)
Trial: 38432247
Drug: Cetuximab 500
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 500 mg/m2
Trial: 38432714
Drug: Prenatal supplementation
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal supplementation (daily oral multiple micronutrient supplementation including 50 μg/d of vitamin B-12)
Trial: 38432714
Drug: Postnatal supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postnatal supplementation (postnatal supplement including 50 μg/d of vitamin B-12)
Trial: 38433191
Drug: 5-FU (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (200 µg/ml) and LMWH (5 IU/ml)
Trial: 38433842
Drug: H56:IC31 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H56:IC31 vaccine (5 micrograms, administered intramuscularly at day 84 and day 140)
Trial: 38433842
Drug: H56:IC31 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H56:IC31 vaccine
Trial: 38433842
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard TB treatment only)
Trial: 38434639
Drug: Lactoferrin (Lf)
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin (Lf) in oral nutritional supplements (ONS)
Trial: 38435429
Drug: Pharmacy Integrated
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacy Integrated Community Care (PICC) program - a structured, four-session group-based program guided by experienced pharmacists focusing on medication adherence and diabetes management.
Trial: 38435809
Drug: Opioid-free anaesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-free anaesthesia (sevoflurane-dexmedetomidine with continuous infusion of lidocaine and ketamine)
Trial: 38435809
Drug: Opioid-based anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-based anaesthesia (sevoflurane-remifentanil with morphine transition)